Glibornuride

Identification

Name
Glibornuride
Accession Number
DB08962
Type
Small Molecule
Groups
Investigational, Withdrawn
Description

Glibornuride is a sulfonylurea-type anti-diabetic drug.

Structure
Thumb
Synonyms
  • Glibornurid
  • Glibornurida
  • Glibornuride
  • Glibornuridum
External IDs
RO 6-4563
International/Other Brands
Glutril (Meda Pharma)
Categories
UNII
VP83E7434R
CAS number
26944-48-9
Weight
Average: 366.48
Monoisotopic: 366.161328499
Chemical Formula
C18H26N2O4S
InChI Key
RMTYNAPTNBJHQI-LLDVTBCESA-N
InChI
InChI=1S/C18H26N2O4S/c1-11-5-7-12(8-6-11)25(23,24)20-16(22)19-14-13-9-10-18(4,15(14)21)17(13,2)3/h5-8,13-15,21H,9-10H2,1-4H3,(H2,19,20,22)/t13-,14+,15+,18+/m1/s1
IUPAC Name
3-[(1S,2S,3R,4R)-3-hydroxy-4,7,7-trimethylbicyclo[2.2.1]heptan-2-yl]-1-(4-methylbenzenesulfonyl)urea
SMILES
CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N[[email protected]@H]1[[email protected]](O)[[email protected]]2(C)CC[[email protected]]1C2(C)C

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololAcebutolol may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
AcenocoumarolGlibornuride may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AlbiglutideAlbiglutide may increase the hypoglycemic activities of Glibornuride.Approved
AlogliptinAlogliptin may increase the hypoglycemic activities of Glibornuride.Approved
AlprenololAlprenolol may increase the hypoglycemic activities of Glibornuride.Approved, Withdrawn
Aluminium clofibrateAluminium clofibrate may increase the hypoglycemic activities of Glibornuride.Experimental
AripiprazoleThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the hypoglycemic activities of Glibornuride.Investigational
Arsenic trioxideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Asenapine.Approved
AtazanavirThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypoglycemic activities of Glibornuride.Approved
AtorvastatinAtorvastatin may increase the hypoglycemic activities of Glibornuride.Approved
BefunololBefunolol may increase the hypoglycemic activities of Glibornuride.Experimental
BendroflumethiazideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Bendroflumethiazide.Approved
BetamethasoneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BetaxololBetaxolol may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
BevantololBevantolol may increase the hypoglycemic activities of Glibornuride.Approved
BezafibrateBezafibrate may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
BisoprololBisoprolol may increase the hypoglycemic activities of Glibornuride.Approved
BopindololBopindolol may increase the hypoglycemic activities of Glibornuride.Approved
BrexpiprazoleThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Brexpiprazole.Approved, Investigational
BucindololBucindolol may increase the hypoglycemic activities of Glibornuride.Investigational
BufuralolBufuralol may increase the hypoglycemic activities of Glibornuride.Experimental, Investigational
BumetanideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Bumetanide.Approved
BupranololBupranolol may increase the hypoglycemic activities of Glibornuride.Approved
BuserelinThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Buserelin.Approved, Investigational
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Glibornuride.Approved
CarbocisteineThe risk or severity of adverse effects can be increased when Glibornuride is combined with Carbocisteine.Approved, Investigational
CarteololCarteolol may increase the hypoglycemic activities of Glibornuride.Approved
CarvedilolCarvedilol may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
CeliprololCeliprolol may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
CeritinibThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Ceritinib.Approved
ChloramphenicolThe metabolism of Glibornuride can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorpropamideGlibornuride may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Chlorthalidone.Approved
CimetidineThe serum concentration of Glibornuride can be increased when it is combined with Cimetidine.Approved, Investigational
CiprofibrateCiprofibrate may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
ClofibrateClofibrate may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
ClofibrideClofibride may increase the hypoglycemic activities of Glibornuride.Experimental
CloranololCloranolol may increase the hypoglycemic activities of Glibornuride.Experimental
ClorindioneGlibornuride may increase the anticoagulant activities of Clorindione.Experimental
ClozapineThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Clozapine.Approved
CorticotropinThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Cortisone acetate.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Cyclopenthiazide.Experimental
Cyproterone acetateThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
DabrafenibThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Dabrafenib.Approved, Investigational
DanazolThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Danazol.Approved
DarunavirThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Darunavir.Approved
DesogestrelThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Desogestrel.Approved
DexamethasoneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Diazoxide.Approved
DicoumarolGlibornuride may increase the anticoagulant activities of Dicoumarol.Approved
DienogestThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Dienogest.Approved
DiphenadioneGlibornuride may increase the anticoagulant activities of Diphenadione.Experimental
DisopyramideGlibornuride may increase the hypoglycemic activities of Disopyramide.Approved
DrospirenoneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Drospirenone.Approved
DulaglutideDulaglutide may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Glibornuride.Approved
EpanololEpanolol may increase the hypoglycemic activities of Glibornuride.Experimental
EpinephrineThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Epinephrine.Approved, Vet Approved
ErtugliflozinErtugliflozin may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
EsmololEsmolol may increase the hypoglycemic activities of Glibornuride.Approved
EstradiolThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
Estrone sulfateThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Etacrynic acid.Approved, Investigational
EthanolThe risk or severity of adverse effects can be increased when Glibornuride is combined with Ethanol.Approved
Ethinyl EstradiolThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Ethinyl Estradiol.Approved
Ethyl biscoumacetateGlibornuride may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Ethynodiol diacetate.Approved
EtofibrateEtofibrate may increase the hypoglycemic activities of Glibornuride.Approved
EtonogestrelThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Etonogestrel.Approved, Investigational
EverolimusThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Everolimus.Approved
ExenatideExenatide may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
FenofibrateFenofibrate may increase the hypoglycemic activities of Glibornuride.Approved
Fenofibric acidFenofibric acid may increase the hypoglycemic activities of Glibornuride.Approved
FluconazoleThe serum concentration of Glibornuride can be increased when it is combined with Fluconazole.Approved, Investigational
FludrocortisoneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Fludrocortisone.Approved, Investigational
FluindioneGlibornuride may increase the anticoagulant activities of Fluindione.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Fosamprenavir.Approved
FurosemideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Furosemide.Approved, Vet Approved
GemfibrozilGemfibrozil may increase the hypoglycemic activities of Glibornuride.Approved
GliclazideGlibornuride may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideGlibornuride may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideGlibornuride may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideGlibornuride may increase the hypoglycemic activities of Glyburide.Approved
GoserelinThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Goserelin.Approved
HistrelinThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Histrelin.Approved
HydrochlorothiazideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
IloperidoneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Iloperidone.Approved
IndapamideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Indapamide.Approved
IndenololIndenolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
IndinavirThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Indinavir.Approved
Insulin AspartGlibornuride may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirGlibornuride may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineGlibornuride may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineGlibornuride may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanGlibornuride may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproGlibornuride may increase the hypoglycemic activities of Insulin Lispro.Approved
LabetalolLabetalol may increase the hypoglycemic activities of Glibornuride.Approved
LandiololLandiolol may increase the hypoglycemic activities of Glibornuride.Investigational
LanreotideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Lanreotide.Approved
LeuprolideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Leuprolide.Approved, Investigational
LevobunololLevobunolol may increase the hypoglycemic activities of Glibornuride.Approved
LevonorgestrelThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LinagliptinLinagliptin may increase the hypoglycemic activities of Glibornuride.Approved
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Glibornuride.Approved, Investigational, Nutraceutical
LiraglutideLiraglutide may increase the hypoglycemic activities of Glibornuride.Approved
LopinavirThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Lopinavir.Approved
LurasidoneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Lurasidone.Approved, Investigational
MecaserminGlibornuride may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrogestoneThe serum concentration of Glibornuride can be decreased when it is combined with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MepindololMepindolol may increase the hypoglycemic activities of Glibornuride.Experimental
MestranolThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Mestranol.Approved
MethotrimeprazineThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
MethyclothiazideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Methyclothiazide.Approved
MethylprednisoloneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MetipranololMetipranolol may increase the hypoglycemic activities of Glibornuride.Approved
MetolazoneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Metolazone.Approved
MetoprololMetoprolol may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
MetreleptinMetreleptin may increase the hypoglycemic activities of Glibornuride.Approved
MiconazoleMiconazole may increase the hypoglycemic activities of Glibornuride.Approved, Investigational, Vet Approved
MifepristoneGlibornuride may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
NadololNadolol may increase the hypoglycemic activities of Glibornuride.Approved
NateglinideGlibornuride may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololNebivolol may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
NelfinavirThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Nelfinavir.Approved
NiacinThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NilotinibThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Nilotinib.Approved, Investigational
NorethisteroneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Norethisterone.Approved
NorgestimateThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Norgestimate.Approved, Investigational
OctreotideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Octreotide.Approved, Investigational
OlanzapineThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Olanzapine.Approved, Investigational
OxprenololOxprenolol may increase the hypoglycemic activities of Glibornuride.Approved
PaliperidoneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Paliperidone.Approved
PasireotideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Pasireotide.Approved
PenbutololPenbutolol may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
PentamidineThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Pentamidine.Approved, Investigational
PhenindioneGlibornuride may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonGlibornuride may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PindololPindolol may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
PioglitazonePioglitazone may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
PiperazineThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Pipotiazine.Approved, Investigational
Platelet Activating FactorPlatelet Activating Factor may increase the hypoglycemic activities of Glibornuride.Experimental
PolythiazideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Polythiazide.Approved
PractololPractolol may increase the hypoglycemic activities of Glibornuride.Approved
PrednisoloneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of heart failure can be increased when Pregabalin is combined with Glibornuride.Approved, Illicit, Investigational
ProbenecidThe protein binding of Glibornuride can be decreased when combined with Probenecid.Approved, Investigational
ProgesteroneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Progesterone.Approved, Vet Approved
PropranololPropranolol may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
QuetiapineThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Quetiapine.Approved
QuinethazoneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Quinethazone.Approved
QuinineGlibornuride may increase the hypoglycemic activities of Quinine.Approved
RanitidineThe serum concentration of Glibornuride can be increased when it is combined with Ranitidine.Approved
RepaglinideGlibornuride may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RifampicinThe serum concentration of Glibornuride can be decreased when it is combined with Rifampicin.Approved
RisperidoneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Ritonavir.Approved, Investigational
RonifibrateRonifibrate may increase the hypoglycemic activities of Glibornuride.Experimental
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
SaquinavirThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Saquinavir.Approved, Investigational
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Glibornuride.Approved
SimfibrateSimfibrate may increase the hypoglycemic activities of Glibornuride.Experimental
SirolimusThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Sirolimus.Approved, Investigational
SitagliptinSitagliptin may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
SotalolSotalol may increase the hypoglycemic activities of Glibornuride.Approved
SulfadiazineGlibornuride may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleGlibornuride may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleGlibornuride may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SunitinibGlibornuride may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TacrolimusThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Tacrolimus.Approved, Investigational
TalinololTalinolol may increase the hypoglycemic activities of Glibornuride.Investigational
TemsirolimusThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Temsirolimus.Approved
TertatololTertatolol may increase the hypoglycemic activities of Glibornuride.Experimental
TimololTimolol may increase the hypoglycemic activities of Glibornuride.Approved
TioclomarolGlibornuride may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Tipranavir.Approved, Investigational
TolazamideGlibornuride may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideGlibornuride may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TorasemideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Torasemide.Approved
TriamcinoloneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TriptorelinThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TroglitazoneTroglitazone may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
UbidecarenoneThe therapeutic efficacy of Glibornuride can be increased when used in combination with Ubidecarenone.Approved, Investigational, Nutraceutical
VildagliptinVildagliptin may increase the hypoglycemic activities of Glibornuride.Approved, Investigational
VoriconazoleThe serum concentration of Glibornuride can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Vorinostat.Approved, Investigational
WarfarinGlibornuride may increase the anticoagulant activities of Warfarin.Approved
ZiprasidoneThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Ziprasidone.Approved
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,654,357.

General References
Not Available
External Links
KEGG Drug
D02427
PubChem Compound
12818200
PubChem Substance
310264926
ChemSpider
16735831
ChEBI
135545
ChEMBL
CHEMBL529888
Drugs.com
Drugs.com Drug Page
Wikipedia
Glibornuride
ATC Codes
A10BB04 — Glibornuride

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)193-195U.S. Patent 3,654,357.
Predicted Properties
PropertyValueSource
Water Solubility0.0635 mg/mLALOGPS
logP2.09ALOGPS
logP2.48ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)4.32ChemAxon
pKa (Strongest Basic)-3.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area95.5 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity94.73 m3·mol-1ChemAxon
Polarizability38.55 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as bicyclic monoterpenoids. These are monoterpenoids containing exactly 2 rings, which are fused to each other.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Monoterpenoids
Direct Parent
Bicyclic monoterpenoids
Alternative Parents
Tosyl compounds / Benzenesulfonamides / Aromatic monoterpenoids / Benzenesulfonyl compounds / Sulfonylureas / Organosulfonic acids and derivatives / Aminosulfonyl compounds / Secondary alcohols / Organic carbonic acids and derivatives / Cyclic alcohols and derivatives
show 4 more
Substituents
Aromatic monoterpenoid / Benzenesulfonamide / Bornane monoterpenoid / Bicyclic monoterpenoid / Tosyl compound / Benzenesulfonyl group / Sulfonylurea / Toluene / Monocyclic benzene moiety / Benzenoid
show 18 more
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available

Drug created on May 30, 2014 11:19 / Updated on December 01, 2017 16:11